



Androgen Society

# PROGRAM BOOK

THE ANDROGEN SOCIETY  
4TH ANNUAL MEETING

**APRIL 21 – 23, 2022**

JW Marriot Orlando Bonnet Creek  
*Orlando, Florida*

**President Hugh Jones, MD**

*Welcomes you to the Androgen  
Society 4th Annual Meeting.*

**natesto**<sup>®</sup>  
(testosterone) nasal gel  



**VISIT us at the NATESTO<sup>®</sup> booth to learn more about a DIFFERENT TYPE of T THERAPY.** T=testosterone.



Actor portrayals.



**ACERUS**  
PHARMA

NATESTO<sup>®</sup> is a registered trademark of Acerus Biopharma Inc.  
The Acerus Pharma logo is a trademark of Acerus Pharmaceuticals Corporation.

© 2022 Acerus Pharmaceuticals Corporation.

NAT-US-0150 03/22

# TABLE OF CONTENTS

## Androgen Society

4th Annual Meeting  
April 21 - 23, 2022  
JW Marriott Orlando Bonnet Creek Resort & Spa  
Orlando, Florida

Welcome Message .....	2
2021 - 2022 Board of Directors .....	2
CME Information.....	3
Faculty Disclosure Link.....	4
Online CME Submission.....	5
Scientific Program .....	6
Speaker Biographies .....	10
Industry Satellite Symposium Event .....	18
Industry Support .....	19
Exhibit Hall Floor Plan .....	21

## GENERAL MEETING INFORMATION

### Registration/Information Desk Hours

*Location: Palm Foyer*

Thursday, April 21, 2022	5:00 p.m. – 6:30 p.m.
Friday, April 22, 2022	7:00 a.m. – 5:30 p.m.
Saturday, April 23, 2022	6:30 a.m. – 6:00 p.m.

### Welcome Reception

*Location: Palm Ballroom C*

Friday, April 22, 2022	6:00 p.m. – 7:30 p.m.
------------------------	-----------------------

### Exhibit Hall Hours

*Location: Palm Ballroom C*

Friday, April 22, 2022	9:30 a.m. – 4:00 p.m.
Saturday, April 23, 2022	7:00 a.m. – 11:00 a.m.

### Androgen Society 2022 Abstracts

A full listing of all meeting abstracts can be found online:

[as.association-service.org/docs/meetings/andro2204/  
androgen-society-abstracts-2022.aspx](https://as.association-service.org/docs/meetings/andro2204/androgen-society-abstracts-2022.aspx)



*\*Note that some abstracts were withdrawn after acceptance. Those numbers are not listed in the schedule or in the online abstract gallery.*

# WELCOME MESSAGE



Dear Colleagues and Friends,

On behalf of the Androgen Society Board, I would like to welcome you to the 4th Annual Meeting of the Androgen Society at the JW Marriot Bonnet Creek, Orlando, Florida, USA. This is a return to an in-person meeting where we can meet and network. The virtual meeting we had in April 2021 was a success but this type of meeting cannot replicate the ability to meet up and have lively discussions between colleagues and experts in the field of androgens. However, due to the difficulties that still remain in the world we decided to open the meeting with a virtual component so that clinicians and scientists can attend from around the world.

The Androgen Society was formed to provide a forum which includes all health professionals from any medical or scientific speciality to learn, discuss and give up to date new original research in the field of androgens, especially testosterone deficiency and its management.

An exciting educational and up to date scientific and clinical findings will be presented in a wide ranging programme. The meeting commences on Thursday evening with a Welcome and Keynote Lecture on Androgens Society and Behaviour followed by a chance to meet up with other attendees. This is followed by two full days of talks from experts from different disciplines in medicine. These include Men's Health, Andrology, Obesity, Diabetes, Endocrinology, Cardiology, Hematology, Neurology, Primary Care, Fertility, Gynecology, Urology.

Highlights of this meeting include lectures on the role of testosterone in mortality, neurodegenerative disease and diabetes including the T4DM study which is the largest published RCT of testosterone therapy. Important areas that will be presented are on Male Contraception, COVID-19, Gonadotropins and Aromatase Inhibitors in male infertility, fertility after androgen steroid abuse and the effects of testosterone on metabolism in women and the risk of breast cancer. Polycythemia, clotting and cardiovascular risk of testosterone therapy in men will be discussed.

The programme provides us with specific areas related to androgens which I believe will be of interest to you from an educational perspective and will provide new data from recent research. I look forward to seeing you at the meeting and joining with specialists and colleagues for what I feel will be an exceptional experience.

I look forward to meeting you in Orlando for the 4th Annual Meeting of the Androgen Society.

Sincerely,

Hugh Jones

President

## ANDROGEN SOCIETY BOARD OF DIRECTORS 2021 - 2022

### OFFICERS

#### President

Hugh Jones, MD

#### Vice President

Abdulmaged M. Traish, MBA, PhD

#### Treasurer

Martin Miner, MD

#### Secretary

Michael Zitzmann, MD, PhD

#### Immediate Past President

Abraham Morgentaler, MD, FACS

#### Board Representative

Adrian S. Dobs, MD, MHS

### Program Committee

Michael Zitzmann, MD, PhD

### EXECUTIVE OFFICE

#### Executive Director

Heather Swanson

#### Associate Director

Brittany Beissel

#### ANDRO Executive Office

1100 E. Woodfield Road, Suite 350

Schaumburg, IL 60173

Phone: (847) 517-7225

Fax: (847) 517-7229

androgensociety@wjweiser.com



# CME INFORMATION

## Educational Needs:

The cause for many neurodegenerative diseases, such as Parkinson's disease, is unknown. Further, sex differences are evident in many neurodegenerative diseases. Indeed, Parkinson's disease, a progressive neurodegenerative disease that is characterized by loss of motor function, impacts aging men more than women. Currently, there is no cure or treatment for many neurodegenerative diseases, such as Parkinson's disease. Therefore, understanding what is driving these sex differences may lead to therapeutics that could slow the progression of these neurodegenerative diseases and thus increase the health span of many patients.

A defective, mutated androgen receptor may lead to variable phenotypes of androgen insensitivity in humans. Also, the CAG repeat polymorphism in exon 1 of the androgen receptor gene modulates androgen effects; in vitro, transcription of androgen-dependent target genes is attenuated with increasing length of triplet residues. Clinically, the CAG repeat polymorphism causes significant modulations of androgenicity in various tissues and psychological traits in healthy eugonadal men: the longer the repeat tracts, the less pronounced is the androgen effect when individuals with similar testosterone concentrations are compared. Furthermore, as effects of testosterone substitution are markedly influenced by the number of CAG repeats, the pharmacogenetic implications of this polymorphism are likely to have a significant role in future testosterone treatment of hypogonadal men. Thresholds at which testosterone treatment should be initiated, as well as androgen dosage, might be tailored according to the receptor polymorphism.

T treatment in older men with functional hypogonadism increased serum T levels to the mid-normal range. The increase in T concentration significantly improves sexual activity as well as significantly increased sexual desire and erectile function. Men who received T reported slightly better mood and lower severity of depressive symptoms than those who received placebo. Men in the T group were also more likely than those in the placebo group to report that their energy was better. T therapy improved bone mineral density and improved anemia of any cause. The rates of adverse events were similar in the two groups.

According to the contemporary published peer-reviewed literature reporting on the treatment of men with benign prostatic hyperplasia (BPH) or androgenetic alopecia (AGA) finasteride or dutasteride elicit some undesirable adverse effects in some but not all individuals. One key *indisputable piece* of evidence noted in almost all clinical studies with finasteride and dutasteride was that these drugs cause some aspect of sexual dysfunction in a subset of men, irrespective of age, dose, or length of study. In some patients, the sexual adverse effects of finasteride or dutasteride were persistent or irreversible. Preclinical studies, albeit limited demonstrated that finasteride and dutasteride reduce endothelial (eNOS) and neural (nNOS) nitric oxide synthases expression and activities, induce trabecular smooth muscle death, increase connective tissue deposition in penile corpora cavernosa, leading to fibrosis, poor tissue compliance and erectile dysfunction (ED).

Several reports have noted increased depression, anxiety, and suicidal ideation in a subset of men treated with these drugs. Based on the available body of evidence, finasteride and dutasteride induce a constellation of sexual, neurological and physical adverse side effects in a subset of men treated with these drugs for BPH or AGA. These adverse events may become persistent or irreversible in some men. These constellations of symptoms constitute the bases for PFS, in susceptible individuals, attributed to their epigenetic susceptibility or predisposition. At present, clinical studies provided either incomplete or inadequate assessment of adverse events and often with limited or inaccurate data reporting about harm. Thus, diagnosis and treatment of PFS will remain a challenging for patients and clinicians alike.

Hypogonadism is common among men with T2DM. Testosterone treatment in hypogonadal men with T2DM leads to profound improvements in glycemic control and can result in remission of T2DM.

It is important for attendees of this conference to obtain information on the potential use of androgens in hormonal male contraception.

A review of the biochemical evidence indicating that testosterone is involved in promoting insulin sensitivity through modification of insulin signaling pathways, glucose utilization by stimulating glucose uptake, glycolysis and mitochondrial oxidative phosphorylation is needed in the field of andrology.

Prevalence of Peyronie's disease (PD) in the USA is 0.7% - 11% and PD is an under-diagnosed condition. Peyronie's disease often occurs in older men with a typical age of onset of 50-60 years and testosterone production declines with aging. And low testosterone levels and Peyronie's disease shares common risk factors like obesity, DM, ageing etc. There is a possible relation with pathophysiology of PD and testosterone deficiency. Urologists need to be aware of testosterone deficiency and Peyronie's disease may coexist. And replacement of testosterone may influence the outcomes of PD treatment.

Testosterone (T) is the most abundant biologically active hormone in women and Testosterone therapy treats many symptoms of hormone deficiency in both pre and postmenopausal women. However, unlike estrogen and progestins, there is a paucity of data regarding the incidence of breast cancer in women treated with testosterone therapy.

Today there is evidence that Testosterone treatment, sometimes combined with an Aromatase inhibitor to prevent aromatization of androgens to estrogens, reduces breast cancer risk. Furthermore, Testosterone pellet implants combined with an aromatase inhibitor in the neoadjuvant setting, before or concurrent with chemotherapy reduces cancer volume supporting the Testosterone direct antiproliferative, protective and therapeutic effect.

## Educational Objectives:

At the conclusion of the Androgen Society 4th Annual Meeting, attendees will be able to:

1. Discuss some of the broader social and evolutionary implications of testosterone.
2. Identify the primary reasons for the longevity gap between men and women.
3. Identify the primary interventions for reducing this longevity gap.
4. Discuss the prevalence of obesity in the US and its association with mortality.
5. Review the basic pharmacologic options for obesity treatment.
6. Review the novel uses of Glucagon-Like Peptide 1 Agonists in Obesity treatment.
7. Review how PDE-5 inhibitors may improve longevity in men.
8. Discuss known causes of male hypogonadism.
9. Review the recent evidence of the phenomena of testosterone decline in younger men.
10. List postulated causes of testosterone decline in men.
11. Discuss current treatments for male hypogonadism.
12. Identify future directions of research and treatment modalities.
13. Discuss the advantages and disadvantages of T therapy in older men with functional hypogonadism.
14. Discuss the indications and potential benefits of T therapy in men with functional hypogonadism.
15. List options for medical therapy of men with functional hypogonadism.
16. Discuss the diagnosis and management of functional hypogonadism.
17. Discuss the data that shows male erectile dysfunction precedes CV disease by 3-5 years.
18. Review male hypogonadism, which is associated with low libido, loss of erection, loss of stamina.
19. Discuss the evidence of hematorit and clotting altering clinical practice in conjunction with published guidelines.
20. Discuss the physiology of free steroid hormones and the impact of changes in binding protein concentrations.
21. Review evidence supporting the clinical relevance of free testosterone.
22. Discuss advantages and disadvantages of available methods to determine free testosterone.
23. Discuss integration of free testosterone in the diagnostic workup of male hypogonadism.
24. Discuss the association between testosterone levels and pathophysiology of Peyronie's disease.
25. Evaluate the relationship of plaque size and curvature severity with testosterone levels in Peyronie's disease.

# CME INFORMATION

26. Discuss the evaluation of testosterone as a predictive factor in the medical treatment of Peyronie's disease.
27. Discuss the appropriate testosterone therapy Improving treatment outcomes for Peyronie's disease.
28. Review the role of testosterone in metabolic diseases to identify/diagnose low testosterone as a comorbidity.
29. Investigate treatment options using testosterone therapy to more effectively manage the patient and obtain optimal outcomes.
30. Discuss the prevalence of hypogonadism in men with T2DM.
31. Discuss the potential benefits of testosterone therapy for patients with hypogonadism and T2DM.
32. Describe the biochemical and gonadal axis changes with male obesity and delineate the interventional techniques to possibly address these perturbations.
33. Evaluate possible hormonal therapies that may be beneficial in the obese male population.
34. Discuss testosterone and mortality in men with a focus on new data from more recent studies.
35. Discuss recent preclinical and clinical findings that indicate that 5 $\alpha$ -R inhibitors evoke not only beneficial, but also adverse effects.
36. Recognize PFS has yet to be recognized by the medical community, even though several patients do present with very severe, peculiar, and classical symptoms and NIH added PFS to its Genetic and Rare Disease Information Center.
37. Discuss that contrary to PFS, persistent side effects arising from treatment with other drugs are well-recognized and accepted while those persistent adverse side effects arising from finasteride treatment are fiercely denied.
38. Discuss endocrinological aspects about androgens in women.
39. Review clinical observations on the effects of androgens in the breast.
40. Review experimental data about the protective role of Testosterone in the mammary gland.
41. Discuss observational clinical studies supporting that Testosterone treatment in women reduces breast cancer risk.
42. Discuss the possible therapeutic role of Testosterone administration in combination with an aromatase inhibitor in breast cancer patients, even before or, concurrent with chemotherapy.
43. Review how hormonal male contraception works in men.
44. Discuss current progress in the use of transdermal testosterone/ nesterone gel for male contraception.
45. Demonstrate that men will accept hormonal male contraception.
46. Discuss the sex differences in neurodegenerative disease risk.
47. Discuss the role of androgens on neurodegenerative disease risk.
48. Discuss potential therapeutic options.
49. Describe the mechanism of male infertility due to long-term use of androgens or human chorionic gonadotropin.
50. Identify the likely time to recovery after the long-term use of androgens or human chorionic gonadotropin.
51. Describe an evidence-based approach to the evaluation and management of male infertility after the long-term use of androgens or human chorionic gonadotropin.
52. Discuss the recent studies with patients treated to target levels of testosterone demonstrate reduced mortality, especially in men with previous myocardial infarction, diabetes and CKD.
53. Discuss why serum testosterone is to be routinely measured in men with the metabolic syndrome and T2DM.
54. Describe an assessment of insulin resistance and factors associated with it permeating into clinical practice.
55. Review up to date evidence-based knowledge on the appropriate use of hormonal therapies in the management of prostate cancer with an emphasis on men who may also have co-existing cardiac conditions.
56. Review mechanisms by which cardio/metabolic disturbances can occur in men undergoing ADT for prostate cancer.
57. Review expanding knowledge on novel second generation therapies used in the management of men with prostate cancer.
58. Discuss the prostate saturation theory.
59. Identify the potential protective effects of testosterone in the setting of localized prostate cancer.
60. Review how testosterone effects prostate cancer cell growth.
61. Review the science and evidence regarding the use of testosterone therapy in men with advanced prostate cancer.
62. Discuss the advantages and disadvantages of genetic analyses in andrology.

63. Discuss the indications and potential benefits of androgen receptor diagnostics in andrology.
64. List options for testosterone therapy according to genetic profile of the androgen receptor.
65. Discuss the diagnoses and management testosterone treatment according to genetics.

## Accreditation Statement

### SAPS CME ACCREDITATION STATEMENT:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Medical Association of Georgia through the joint providership of the Southern Alliance for Physician Specialties CME and the Androgen Society. The Southern Alliance for Physician Specialties CME is accredited by the Medical Association of Georgia to provide continuing medical education for physicians.

The Southern Alliance for Physician Specialties CME designates this live activity for a maximum of **16.50 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Non-physician healthcare professionals will receive a Certificate of Attendance. For information on the applicability and acceptance of Certificates of Attendance for educational activities certified for **AMA PRA Category 1 Credit™** from organizations accredited by the ACCME, please consult your professional licensing board.

### General Disclaimer

The statements and opinions contained in this program are solely those of the individual authors and contributors and not of the Androgen Society. The appearance of the advertisements is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. The content of this publication may contain discussion of off-label uses of some of the agents mentioned. Please consult the prescribing information for full disclosure of approved uses. The Androgen Society disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the abstracts or advertisements.

### Special Assistance

We encourage participation by all individuals. If you have a disability, advance notification of any special needs will help us better serve you. Call (847) 517-7225 if you require special assistance to fully participate in the meeting.

### Disclosure Report

The disclosure report for the Androgen Society 4th Annual Meeting can be found online at:

[virtual.association-service.org/docs/as/disclosures.aspx](http://virtual.association-service.org/docs/as/disclosures.aspx)



# ONLINE CME SUBMISSION

## The Androgen Society 4th Annual Meeting

Androgen Society

**April 21 - 23, 2022**

**JW Marriott Orlando Bonnet Creek**

**Orlando, Florida**



CME Submissions are Going Green by Going Online!

*Please note the electronic CME submission form will open Saturday, April 23 at 8:00 a.m. Central and close on Sunday, May 15 at 11:59 p.m. Central Time.*

*The CME submission form may be accessed via the link below or the QR code to the left.  
[virtual.association-service.org/as/cme](http://virtual.association-service.org/as/cme)*

**The CME Certification Worksheet will open Saturday, April 23 at 8:00 a.m. Central Time and close on Sunday, May 15 at 11:59 p.m. Central Time.**

- 1. Record your attendance.** Attendees should claim only credit commensurate with the extent of their participation in the activity. When complete, click the "Submit CME Time Claimed" button.
- 2. Complete Evaluation.** Approximately 4 weeks post-meeting, you will receive an email with a link to the CME Evaluation Survey. Follow the link to complete the survey online. The CME Evaluation will be open for 60 days.
- 3. Access your Certificate.** Immediately following completion of the CME Evaluation Survey, you will be redirected to the certificate site. Once you sign-in you will have access to your CME or Participation Certificate.

For physicians to officially receive *AMA PRA Category 1 Credit™* and for other healthcare providers to document their attendance, participants are required to complete both this attendance worksheet and the activity evaluation online.

*Attendance and evaluations will be tracked.*

If you have difficulties with the online CME submission, you may contact us via email at [cmeinfo@wjweiser.com](mailto:cmeinfo@wjweiser.com) or via phone during regular business hours at (847) 517-7225.

# SCIENTIFIC PROGRAM

All sessions will be located in **Palm AB** unless otherwise noted. Speakers and times are subject to change.

## THURSDAY, APRIL 21, 2022

### OVERVIEW

5:00 p.m. - 6:30 p.m. **Registration/Information Desk**  
Location: *Palm Foyer*

9:30 a.m. - 10:00 a.m. **Break & Networking in the Exhibit Hall**

### GENERAL SESSION

5:00 p.m. - 5:15 p.m. **President's Welcome**  
President: Hugh Jones, MD

10:00 a.m. - 11:30 a.m. **Hot Topics**  
Moderators: Larry I. Lipshultz, MD  
Abraham Morgentaler, MD, FACS

5:15 p.m. - 5:30 p.m. **Androgen Society Journal Update**  
Speakers: Abdulmageed M. Traish, MBA, PhD  
Sophie Reisz

10:00 a.m. - 10:20 a.m. **Hematorrit and Clotting: Issues of TRT?**  
Speaker: Sudarshan Ramachandran, PhD

5:30 p.m. - 6:30 p.m. **Keynote Address: Androgens, Society & Behavior**  
Speaker: Carole Hooven, PhD

10:20 a.m. - 10:40 a.m. **SHBG and Free T: Special Roles in Androgen Physiology**  
Speaker: Leen Antonio, MD, PhD

6:30 p.m. **Adjourn**

10:40 a.m. - 11:00 a.m. **Is There A Synergistic Role for GH Secretagogues in Treatment of Androgen**  
Speaker: Jason R. Kovac, MD, PhD, FACS, FRCS

## FRIDAY, APRIL 22, 2022

### OVERVIEW

7:00 a.m. - 5:30 p.m. **Registration/Information Desk**  
Location: *Palm Foyer*

11:00 a.m. - 11:20 a.m. **Androgens and Peyronie's Disease**  
Speaker: Ates Kadioglu, MD

9:30 a.m. - 4:00 p.m. **Exhibit Hall Hours**  
Location: *Palm Ballroom C*

11:20 a.m. - 11:30 a.m. **Discussion**

6:00 p.m. - 7:30 p.m. **Welcome Reception in the Exhibit Hall**

11:30 a.m. - 11:45 a.m. **Grandmaster of Testosterone Award**  
Recipient: Hugh Jones, MD

### GENERAL SESSION

8:00 a.m. - 9:30 a.m. **An Overview of Men's Health**  
Moderators: Omer Raheem, MD  
Christina Wang, MD

11:45 a.m. - 1:00 p.m. **Lunch and Coffee in Exhibit Hall**  
Location: *Palm Ballroom C*

8:00 a.m. - 8:20 a.m. **Why Don't Men Live as Long as Women? The Important Role of Male Health Care**  
Speaker: Martin Miner, MD

1:00 p.m. - 1:30 p.m. **Clinical Case Discussion**  
Moderator: Abraham Morgentaler, MD, FACS  
Panelists: Janine David, MD, FECSM  
Larry I. Lipshultz, MD  
Omer Raheem, MD

8:20 a.m. - 8:40 a.m. **The Decline of Testosterone in Men: From Hero to Zero?**  
Speaker: Ranjith Ramasamy, MD

1:30 p.m. - 2:50 p.m. **Metabolism and Androgens**  
Moderators: Sandeep Dhindsa, MD  
Abraham Morgentaler, MD, FACS

8:40 a.m. - 9:00 a.m. **Functional Hypogonadism: Is It Just An Invention For Old Men?**  
Speaker: Abdulmageed M. Traish, MBA, PhD

1:30 p.m. - 1:50 p.m. **The Molecular Basis for Testosterone as an Insulin Sensitizer**  
Speaker: Daniel Kelly, PhD

9:00 a.m. - 9:20 a.m. **Sexual Health is the Portal to Men's Health**  
Speaker: Allen D. Seftel, MD, FACS

1:50 p.m. - 2:10 p.m. **Reversal of T2DM: Mission Possible?**  
Speaker: Farid Saad, DVM, PhD

9:20 a.m. - 9:30 a.m. **Discussion**

2:10 p.m. - 2:25 p.m. **T4DM: Lessons Learned**  
Speaker: Hugh Jones, MD



# SCIENTIFIC PROGRAM

- 2:25 p.m. - 2:40 p.m. **T4DM: And Now? What Impact Should TRT have in Treatment of T2D?**  
Speaker: Paresh Dandona, MD
- 2:40 p.m. - 2:50 p.m. **Discussion**
- 2:50 p.m. - 3:40 p.m. **Non-Testosterone Therapies for Infertility Associated with Testosterone Deficiency**  
Moderator: Michael Zitzmann, MD, PhD
- 2:50 p.m. - 3:10 p.m. **Does Gonadotropin Therapy Have a Role in The Management of Infertility in Men with Obesity-Related Hypogonadism?**  
Speaker: Larry I. Lipshultz, MD
- 3:10 p.m. - 3:30 p.m. **Do Aromatase Inhibitors Have a Role in the Management of Infertility in Men with Obesity-Related Hypogonadism?**  
Speaker: Hugh Jones, MD
- 3:30 p.m. - 3:40 p.m. **Discussion**
- 3:40 p.m. - 4:00 p.m. **Break & Networking in the Exhibit Hall**
- 4:00 p.m. - 4:20 p.m. **Clinical Case Discussion**  
Moderator: Mohit Khera, MD, MBA, MPH  
Panelists: Geoffrey Hackett, MD  
Martin Miner, MD  
Michael Zitzmann, MD, PhD
- 4:20 p.m. - 5:10 p.m. **Androgens and Novel Health Aspects**  
Moderators: Sudarshan Ramachandran, PhD  
Ronald Swerdloff, MD
- 4:20 p.m. - 4:40 p.m. **Sperm Parameters After COVID-19 Vaccination**  
Speaker: Ranjith Ramasamy, MD
- 4:40 p.m. - 5:00 p.m. **5-Alpha Reductase-Inhibitors and Its Effects on the Brain**  
Speaker: Roberto Cosimo Melcangi, PhD
- 5:00 p.m. - 5:10 p.m. **Discussion**
- 5:10 p.m. - 6:00 p.m. **Evening Lecture - Post-Finasteride-Syndrome: The Story of DHT and 5-Alpha-Reductase-Inhibitors**  
Moderators: Roberto Cosimo Melcangi, PhD  
Martin Miner, MD  
Speaker: Abdulmaged M. Traish, MBA, PhD
- 6:00 p.m. - 7:30 p.m. **Welcome Reception in the Exhibit Hall**

## SATURDAY, APRIL 23, 2022

### OVERVIEW

- 6:30 a.m. - 6:00 p.m. **Registration/Information Desk Hours**  
*Location: Palm Foyer*
- 7:00 a.m. - 8:00 a.m. **Breakfast in the Exhibit Hall**  
*Location: Palm Ballroom C*
- 7:00 a.m. - 11:00 a.m. **Exhibit Hall Hours**  
*Location: Palm Ballroom C*

### GENERAL SESSION

- 8:00 a.m. - 8:20 a.m. **Annual Business Meeting**
- 8:20 a.m. - 8:40 a.m. **Does Testosterone Therapy Increase Breast Cancer Risk?**  
Moderators: Mohit Khera, MD, MBA, MPH  
Sharon Parish, MD  
Speaker: Constantine Dimitrakakis, MD, PhD, Ob/Gyn
- 8:40 a.m. - 8:50 a.m. **Discussion**
- 8:50 a.m. - 9:40 a.m. **Androgens in Male Contraception**  
Moderator: Abraham Morgentaler, MD, FACS
- 8:50 a.m. - 9:10 a.m. **Novel Oral Approaches**  
Speaker: Ronald Swerdloff, MD
- 9:10 a.m. - 9:30 a.m. **T-Gel and Nestorone**  
Speaker: Christina Wang, MD
- 9:30 a.m. - 9:40 a.m. **Discussion**
- 9:40 a.m. - 10:25 a.m. **Abstract Session 1**
- 9:40 a.m. - 9:45 a.m. **#1 Higher Risk of Major Adverse Cardiovascular Events After Androgen Deprivation Therapy in Older Patients**  
Presenter: E. David Crawford, MD
- 9:45 a.m. - 9:50 a.m. **#2 Analyses of Real-World Major Adverse Cardiovascular Event Risk by Androgen Deprivation Therapy Drug Class**  
Presenter: E. David Crawford, MD
- 9:50 a.m. - 9:55 a.m. **#3 Reduced Mortality and Different Causes of Death in Men with Functional Hypogonadism, Compared to an Untreated Control Group in a Real-World Registry Study**  
Presenter: Ahmad Haider, MD
- 10:00 a.m. - 10:05 a.m. **#4 Testosterone Therapy in Breast Cancer Survivors**  
Presenter: Rebecca Glaser, MD

# SCIENTIFIC PROGRAM

- 10:05 a.m. - 10:10 a.m. #5 Testosterone Replacement Therapy in Patients with Cachexia: A Contemporary Review of the Literature**  
Presenter: Omer Raheem, MD
- 10:10 a.m. - 10:15 a.m. #6 Long-Term Testosterone Treatment Improves Liver Function Parameters in Men with Functional Hypogonadism: Real-World Data from a Registry**  
Presenter: Ahmad Haider, MD
- 10:15 a.m. - 10:20 a.m. #7 Relationship Between Time of Testing and 24-Hour Average Concentration of Total Testosterone in Hypogonadal Men Treated with an Oral Testosterone Undecanoate Capsule (JATENZO)**  
Presenter: Ronald Swerdloff, MD
- 10:20 a.m. - 10:25 a.m. #8 Comparison Between Oral Testosterone Undecanoate (JATENZO) and a Transdermal Testosterone Gel (AndroGel 1%) in Total Testosterone, Free Testosterone and SHBG After One-year of Therapy**  
Presenter: Ronald Swerdloff, MD
- 10:25 a.m. - 10:45 a.m. Break & Networking**  
*Location: Palm Ballroom C*
- 10:45 a.m. - 11:05 a.m. New Data: Testosterone and Mortality**  
Moderator: Michael Zitzmann, MD, PhD  
Speaker: Bu B. Yeap, MBBS, FRACP, PhD
- 11:05 a.m. - 11:15 a.m. Discussion**
- 11:15 a.m. - 12:05 p.m. Essentials in Androgen Physiology**  
Moderator: Hugh Jones, MD
- 11:15 a.m. - 11:35 a.m. Prevalence and Incidence of TD in Men with Neurodegenerative Disease**  
Speaker: Rebecca L. Cunningham, PhD
- 11:35 a.m. - 11:55 a.m. Male Fertility after Androgenic Steroid Use: How Little We Know**  
Speaker: Bradley D. Anawalt, MD
- 11:55 a.m. - 12:05 p.m. Discussion**
- 12:05 p.m. - 12:15 p.m. Dedication to Education Award**  
Recipient: Christina Wang, MD
- 12:15 p.m. - 1:15 p.m. Industry Sponsored Lunch Symposium**  
*Location: Palm DE*
- 1:15 p.m. - 2:10 p.m. Abstract Session 2**
- 1:15 p.m. - 1:20 p.m. #9 Long-Term Testosterone Therapy Improves Renal Function in Men with Functional Hypogonadism: Experience from an Observational Registry Study**  
Presenter: Karim Sultan Haider MD
- 1:20 p.m. - 1:25 p.m. #10 Changes in Metabolic Parameters and Bone Markers with Oral versus Topical Testosterone**  
Presenter: Fiona Yuen, MD
- 1:25 p.m. - 1:30 p.m. #11 Use of Clomiphene Citrate in Oligospermic Obese Men with Hypogonadism: Retrospective Pilot Study**  
Presenter: Wael Almajed, MBBS
- 1:30 p.m. - 1:35 p.m. #12 Profound, Sustained Weight Loss in Men with Functional Hypogonadism Receiving 13 Years of Long-Term Testosterone Therapy - Clinical Experience of 8, 190 Patient-Years**  
Presenter: Karim Sultan Haider MD
- 1:35 p.m. - 1:40 p.m. #13 Optimizing Body Composition in Men with Androgen Deficiency Secondary to Hypogonadotropic Hypogonadism**  
Presenter: Florence Comite, MD
- 1:40 p.m. - 1:45 p.m. #14 Subcutaneous Testosterone Injections in Hypogonadal Men**  
Presenter: Rodney L. Dennis, MD
- 1:45 p.m. - 1:50 p.m. #15 Sustained Improvement of Lipid Pattern as a Result of Long-Term Testosterone Therapy (TTh) Over 13 Years in Men with Functional Hypogonadism**  
Presenter: Farid Saad, DVM, PhD
- 1:50 p.m. - 1:55 p.m. #16 Beneficial Effects of Testosterone Therapy in Women: The Proof is in the Pudding (Case Presentations and Testimonials)**  
Presenter: Rebecca Glaser, MD
- 1:55 p.m. - 2:00 p.m. #17 Hypogonadism and Intracranial Hypertension, a Case Report and Brief Review**  
Presenter: Trisha Nguyen, MD

# SCIENTIFIC PROGRAM

- 2:00 p.m. - 2:05 p.m. **#18 Effect of Bulbospongiosus Muscles Cutting with Frenular Delta Excision for Treatment Premature Ejaculation (Alaa Aglan Operation)**  
Presenter: Alaa A. Aglan, PHD
- 2:05 p.m. - 2:10 p.m. **#19 Effect of Bulbospongiosus Muscles Cutting with Frenular Delta Excision and Ventral Neurectomy for Treatment of Premature Ejeaculation (Alaa Aglan2 operation)**  
Presenter: Alaa A. Aglan, PHD
- 2:10 p.m. - 4:00 p.m. **The Prostate and The Heart: Androgen Issues?**  
Moderators: E. David Crawford, MD  
Wayne J. G. Hellstrom, MD, FACS
- 2:10 p.m. - 2:30 p.m. **Current Knowledge: Are Androgens Safe for the Heart?**  
Speaker: Geoffrey Hackett, MD
- 2:30 p.m. - 2:50 p.m. **New Results from the Moscow Study: TRT and Insulin Resistance**  
Speaker: Sudarshan Ramachandran, PhD
- 2:50 p.m. - 3:10 p.m. **CVS Implications of ADT Used for Intermediate to High Risk Localized PCa**  
Speaker: Marc B. Garnick MD
- 3:10 p.m. - 3:30 p.m. **Testosterone Therapy in Men with Localized Prostate Cancer**  
Speaker: Mohit Khera, MD, MBA, MPH
- 3:30 p.m. - 3:50 p.m. **T Therapy in Men with Advanced Prostate Cancer**  
Speaker: Abraham Morgentaler, MD, FACS
- 3:50 p.m. - 4:00 p.m. **Discussion**
- 4:00 p.m. - 4:25 p.m. **Break & Networking**  
*Location: Palm Foyer*
- 4:25 p.m. - 5:35 p.m. **Genetics, Metabolites and Thresholds of Androgen Physiology: Do We Need All This?**  
Moderator: Mohit Khera, MD, MBA, MPH
- 4:25 p.m. - 4:45 p.m. **Is Dihydrotestosterone an Endocrine or Paracrine Hormone?**  
Speaker: Jean Paul Deslypere, MD, PhD
- 4:45 p.m. - 5:05 p.m. **Making Clinical Sense of Androgen Receptor Genetics**  
Speaker: Michael Zitzmann, MD, PhD
- 5:05 p.m. - 5:25 p.m. **Guidelines for Androgen Therapy: Do We Need Thresholds?**  
Speaker: Hugh Jones, MD
- 5:25 p.m. - 5:35 p.m. **Discussion**
- 5:35 p.m. - 5:45 p.m. **Closing Remarks**  
President: Hugh Jones, MD

# SPEAKER BIOGRAPHIES

## **Bradley D. Anawalt, MD**

Dr. Anawalt is the Chief of Medicine at the University of Washington Medical Center and Professor and Vice Chair of the Department of Medicine at the University of Washington. His principal areas of research are in male infertility, male hormonal contraception and male reproductive physiology. His excellence in teaching has been recognized with several University of Washington Department of Medicine teaching awards: 2014 Marvin Turck Award for excellence in teaching and clinical care, 2007 Endocrinology Fellowship Teaching Award, and 1999 Paul Beeson Award (selected by the internal medicine residents). He has been the North American editor for the Journal of Clinical Endocrinology (2012-2021), Associate Editor for Endocrine Reviews (2014-2017) and has served twice on the editorial board of the Journal of Clinical Endocrinology and Metabolism (2006-2010 and 2010-2014). He has won outstanding reviewer awards from the Journal of Clinical Endocrinology and Metabolism and the Annals of Internal Medicine. He serves as a consultant to the United States Anti-Doping Agency and consultant to the NCAA Inclusion and Diversity Panel and NCAA Committee on Competitive Safeguards and Medical Aspects of Sports. He has had leadership positions in the United States Endocrine Society including Board of Directors member (2014-2017), Chair of the Hormone Health Network (2006-2010 and 2010-2014) and Clinical Chair of the 2011 Annual Meeting. His clinical focus is in the area of male reproductive endocrinology, and he has received several national and regional awards from his peers for clinical expertise.

## **Leen Antonio, MD, PhD**

Dr. Leen Antonio is an endocrinologist/andrologist at University Hospitals Leuven, Belgium and an assistant professor at Department of Chronic Diseases and Metabolism (CHROMETA) of KU Leuven, Belgium. She has a specific interest in male hypogonadism, male infertility and reproductive endocrinology. Her research focuses on clinical research in andrology, male reproductive endocrinology and steroid hormones.

## **E. David Crawford, MD**

Dr. E. David Crawford is Professor of Urology at the University of California San Diego and former distinguished endowed Professor of Surgery, Urology, and Radiation Oncology, and Head of the Section of Urologic Oncology at the University of Colorado Anschutz Medical Campus in Aurora, Colorado. Dr. Crawford received his medical degree from the University of Cincinnati. His postgraduate training included an internship and residency in urology at the Good Samaritan Hospital in Cincinnati. He subsequently completed a genitourinary cancer fellowship at the University of California Medical Center in Los Angeles.

Dr. Crawford is an internationally-recognized expert in benign prostate hypertrophy, urologic cancers, and in particular, prostate cancer. He has conducted research in the treatment of advanced bladder cancer, metastatic adenocarcinoma of the prostate, hormone refractory prostate cancer, and other areas of urological infections and malignancies. He has authored or coauthored over 810 scientific articles, has published seven textbooks and authored over 60 book chapters. Dr. Crawford was Chairman of the Genitourinary Cancer Committee of the Southwest Oncology Group for 28 years. He is also the Founder and Chairman of the Prostate Conditions Education Council which is responsible for screening nearly four million men for prostate health issues and

reaches more than 200 million people each year with education and awareness information. Dr. Crawford has received many honors and awards, including the CaP Cure Annual Award for Scientific Presentation and has twice been presented with a "Freddie Award" at the AMA International Health and Medical Film Competition for best medical documentaries. He has been recognized as one of the Best Doctors of America for the past two decades, and is recognized as one of the top 20 urologists in the country, for men, by Men's Health Magazine. In 2018 he received the honor of being named the Distinguished Alumnus of the Year from the University of Cincinnati School of Medicine. In May of 2019, he received the Presidential citation from the American Urological Association recognizing for his "tireless role in genitourinary cancer research that has benefited countless urologic cancer patients." He accepted the position of Editor in Chief of Grand Rounds in Urology in June of 2019.

E. David Crawford is Professor of Urology at the University of California San Diego and emeritus distinguished endowed Professor of Surgery, Urology, and Radiation Oncology, and Head of the Section of Urologic Oncology at the University of Colorado Anschutz Medical Campus in Aurora, Colorado. Dr. Crawford received his medical degree from the University of Cincinnati. His postgraduate training included an internship and residency in urology at the Good Samaritan Hospital in Cincinnati. He subsequently completed a genitourinary cancer fellowship at the University of California Medical Center in Los Angeles.

Dr. Crawford is an internationally-recognized expert in benign prostate hypertrophy, urologic cancers, and in particular, prostate cancer. He has conducted research in the treatment of advanced bladder cancer, metastatic adenocarcinoma of the prostate, hormone refractory prostate cancer, and other areas of urological infections and malignancies. He has authored or coauthored over 810 scientific articles, has published seven textbooks and authored over 60 book chapters. Dr. Crawford was Chairman of the Genitourinary Cancer Committee of the Southwest Oncology Group for 28 years. He is also the Founder and Chairman of the Prostate Conditions Education Council which is responsible for screening nearly four million men for prostate health issues and reaches more than 200 million people each year with education and awareness information. Dr. Crawford has received many honors and awards, including the CaP Cure Annual Award for Scientific Presentation and has twice been presented with a "Freddie Award" at the AMA International Health and Medical Film Competition for best medical documentaries. He has been recognized as one of the Best Doctors of America for the past two decades, and is recognized as one of the top 20 urologists in the country, for men, by Men's Health Magazine. In 2018 he received the honor of being named the Distinguished Alumnus of the Year from the University of Cincinnati School of Medicine. In May of 2019, he received the Presidential citation from the American Urological Association recognizing for his "tireless role in genitourinary cancer research that has benefited countless urologic cancer patients." He accepted the position of Editor in Chief of Grand Rounds in Urology in June of 2019.



# SPEAKER BIOGRAPHIES

## **Rebecca L. Cunningham, PhD**

Dr. Rebecca Cunningham studies the role of steroid hormones, specifically androgens. Most of her team's research has been focused on androgen signaling mechanisms and defining the effects of androgens on central nervous system function. One of Dr. Cunningham's long-term research goals is to determine how aging alters neuronal steroid hormonal responses in an oxidative stress environment, a key characteristic of aging and neurodegeneration. She has shown that androgens can either be neuroprotective or damaging, and these effects are dependent on the oxidative stress environment. In pursuing this goal, Dr. Cunningham and team use in vitro, in vivo, and clinical approaches to understand how androgens affect brain function. Hopefully this research will expand the understanding of how steroid hormones impact the brain. At the same time, she seeks to gain new insights that can lead to a better understanding of the role of sex in central nervous system disorders.

## **Paresh Dandona, MD**

Dr. Dandona is a Distinguished Professor of Medicine and chief of the Division of Endocrinology, Diabetes and Metabolism, at the University at Buffalo, The State University of New York. He is also the founder and director of the Diabetes–Endocrinology Center of Western New York in Buffalo. Previously, he served as director of Diabetes and Metabolism at the Royal Free Hospital School of Medicine at the University of London, England, for 14 years. One of the world's leading experts in the treatment of diabetes and vascular disease, Dr. Dandona is a Rhodes Scholar from India, trained at the University of Oxford and the University of London.

Dr. Dandona has published more than 590 publications in peer-reviewed medical journals, and has presented keynote lectures on diabetes and insulin resistance at many national and international conferences. He is the founder editor of Metabolic Syndrome and Related Disorders, and is or has been on the editorial boards of the Journal of Clinical Endocrinology and Metabolism, Diabetes Care, Current Diabetes Reviews and Journal of Diabetes.

## **Janine David, MD**

Dr. Janine David is a GP who specialises in Men's Health. She has been a GP partner and trainer in Portway Surgery, Porthcawl, UK since 2005 and also works as an Associate Specialist in Urology at the Princess of Wales Hospital in Wales. She has passed the Multidisciplinary Joint Committee of Sexual Medicine (MJCSM) exam making her a Fellow of the European Committee of Sexual Medicine (FECMSM). She has a particular interest in testosterone deficiency and has run clinical audits throughout the UK to identify ways to improve the health of patients in this often overlooked area.

Dr. David is the founding member of the Primary Care Testosterone Advisory Group ([www.PCTAG.uk](http://www.PCTAG.uk)) and she is a regular speaker both on the national (UK) and international stage. She is also actively involved in clinical research.

## **Jean-Paul Deslypere , MD, PhD**

Dr. Jean-Paul Deslypere followed High School at the Koninklijk Atheneum in Brugge, and got his medical degree summa cum laude from the University of Gent in Belgium in 1977. After graduation he obtained his PhD (Geaggregeerde van het Hoger Onderwijs) in Endocrinology and Metabolic Diseases in 1984 and his Board Certification in Internal Medicine/Endocrinology in 1987. He replaced GP's during their holiday period from 1977 till 1987. During his specialization in Internal Medicine (1977 till 1987) he worked in the Depts. of Intensive Care, A&E, General Internal Medicine, Cardiology, Pneumology, Nephrology, Gastro Enterology and Endocrinology. From 1987 till 1996 he worked in the Dept of Endocrinology and from 1997 till 2001 he worked part time in private practice in Belgium.

## **Sandeep Dhindsa, MD, FACE**

Dr. Sandeep Dhindsa completed his medical schooling from All India Institute of Medical Sciences in New Delhi, India. He did a residency in Internal medicine from State University of New York at Brooklyn and fellowship in Endocrinology from State University of New York at Buffalo in 2002. He is Professor of Medicine and Chief of the Division of Endocrinology and Metabolism at Saint Louis University. His primary area of research is hypogonadism in obesity and type 2 diabetes. He has over 80 publications in peer-review journals. He is a member of Scientific Reproductive Committee of the American Association of Clinical Endocrinologists.

## **Constantine Dimitrakakis, MD, PhD**

Dr. Constantine Dimitrakakis's professional research experience includes laboratory and clinically based breast research at the NIH, USA, with a focus on the effects of Hormone Therapy on breast cancer risk and possible modifications of it.

## **Marc B. Garnick, MD**

Dr. Marc B. Garnick is an expert on urologic cancer. He has dedicated his career to the development of new drug therapies and maintains a practice at the Beth Israel Deaconess Medical Center, and is Gorman Brothers Professor of Medicine at Harvard Medical School.

Dr. Garnick received his medical degree from the University of Pennsylvania School of Medicine and completed his internship and residency at the university's hospital. He has also completed a research and clinical fellowship in oncology with the National Institutes of Health (NIH) and the Dana Farber Cancer Institute of Harvard Medical School.

He is a member of numerous professional organizations, as well as several editorial boards for peer-reviewed publications. Dr. Garnick has authored more than 350 written works, including 6 books, peer reviewed articles and reviews. Most recently, he co-authored an article entitled "Combating Prostate Cancer" which appeared in *Scientific American*, and authored the prostate cancer screening policy guidelines for the American College of Physicians as part of their educational resource for primary care physicians and internists.

# SPEAKER BIOGRAPHIES

Dr. Garnick was the academic principal investigator on the development of Lupron, a widely used hormonal therapy for prostate cancer.

Dr. Garnick has served on numerous United States government sponsored committees on prostate cancer, including the Prostate Cancer Working Group, and the Scientific Advisory Board on Cancer Prevention and the SPORC Grant Funding Mechanism for Prostate Cancer, both of the National Cancer Institutes. He has served as the co-director of the International Conference on Neoadjuvant Hormone Therapy for Prostate Cancer, and is Medical Advisor to the World Book Encyclopedia. He founded the Hershey Family Foundation for Prostate Cancer Research at the Beth Israel Deaconess Medical Center.

## **Geoff Hackett, MD, FRCPI, MRCGP**

Dr. Hackett is past professor of Men's Health and Diabetes at University of Bedfordshire, and a Consultant in Urology and Sexual Medicine at Good Hope Hospital, Birmingham, UK, since 1994. He qualified in medicine in 1974 at King's College Hospital, London, UK, and gained his MD from Keele University, UK, in 2000 on the links between erectile dysfunction (ED) and cardiovascular disease. He has 35 years experience as a primary care physician. Professor Hackett has a major research interest in the role of testosterone in metabolic syndrome and type 2 diabetes and Low Sexual Desire in Women. He is the author of over 130 publications in sexual medicine, and 2 original books on male sexual health and andrology, as well as contributing chapters to several medical textbooks. He is lead author of the British Society for Sexual Medicine (BSSM) guidelines on ED, and the use of testosterone therapy to manage sexual problems in both men and women, co-author of the consensus guidelines on ED and coronary artery disease prediction, Princeton 3 guidelines. Oxford Textbook of Urology, and a panel member for the International Society for Sexual Medicine (ISSM) guidelines on premature ejaculation. In 2012, he won the Zorngiotti-Newman research prize at ISSM for work on testosterone replacement in type 2 diabetes. Professor Hackett is past-President (2005–07) and Treasurer of the BSSM (2009-2014), and a pastmember of the scientific committees of the International Society for Sexual Medicine, and a Chair of the 2015 International Consensus Panel in Sexual Medicine.

He passed the examination for the Fellowship of the European Academy of Sexual Medicine and is a current examiner for the fellowship exam and a member of the executive committee of the European Society for Sexual Medicine.

## **Carole Hooven, PhD**

Dr. Carole Hooven is lecturer and codirector of undergraduate studies in the Department of Human Evolutionary Biology at Harvard University. She earned her BA in Psychology at Antioch College in 1998, and her PhD at Harvard in 2004, studying sex differences and testosterone. She has taught there ever since. Hooven has received numerous teaching awards, and her popular Hormones and Behavior class was named one of the Harvard Crimson's "top ten tried and true."

Dr. Hooven's 2021 book, *T: the Story of Testosterone, the Hormone that Dominates and Divides Us*, has been widely acclaimed: Featured in *The Wall Street Journal's* "10 Books to Read: The Best Reviews of July"; *The Times* (UK)'s Best Books of 2021; *Bloomberg Opinion's* 15 Best Nonfiction Books of 2021.

## **Hugh Jones, MD**

Dr. Jones is Consultant Physician & Endocrinologist at Barnsley Hospital NHS Foundation Trust and Honorary Professor of Andrology at the University of Sheffield Medical School. He is also Honorary Consultant Endocrinologist at the Royal Hallamshire Hospital, Sheffield. He trained in Biochemistry and subsequently medicine at Sheffield University. Postgraduate training in Medicine, Diabetes and Endocrinology in Sheffield and was Lecturer in Medicine at Sheffield University.

He is on the European Association (EAU) of Urology Guideline committee for Male Hypogonadism and the British Society of Sexual Medicine (BSSM) Guideline committee for Adult Testosterone Deficiency. He is Chair of the Academic sub-committee of the Association of British Clinical Diabetologists (ABCD). He is a founder member of the Androgen Society, an international society which is a forum for experts from different medical and scientific disciplines to present and discuss new research into the role of androgens.

The main research theme of the group is the laboratory and clinical investigation of the role of testosterone in the pathogenesis and treatment of coronary heart disease, angina, heart failure, type 2 diabetes and the metabolic syndrome in men. Major discoveries have demonstrated that there is a high prevalence of symptomatic testosterone deficiency in men with T2D and that low testosterone is associated with an increased risk of mortality within populations of men with coronary heart disease and also in type 2 diabetes. Testosterone replacement improves cardiac ischaemia in angina, functional exercise capacity in heart failure, insulin resistance and mortality in type 2 diabetes. Laboratory work has investigated the action of testosterone as an arterial vasodilator, atheroprotective in early arterial lipid streak formation, and its role in glucose and lipid metabolism and an effect on fat depot distribution.

# SPEAKER BIOGRAPHIES

## **Ateş Kadioğlu, MD**

Ateş Kadioğlu is graduated from Istanbul High School in 1977 and from Istanbul Faculty of Medicine in 1983. He served as a resident until 1990 and then as clinical instructor at the same Faculty. He became associate professor in 1994, and then professor in 2000

Prof. Kadioğlu served as the President of the Turkish Society of Andrology between 2002 and 2009. Currently, he is the Honorary President of the Turkish Society of Andrology. He is the head of the Division of Andrology in Istanbul Faculty of Medicine.

He served as the president of the Turkish Association of Urology between 2008 and 2012. Currently, he is vice president of Turkish Association of Urology, coordinator of the Turkish Academy of Urology and editor in chief of Turkish Journal of Urology.

He served as a vice dean of Istanbul Faculty of Medicine between 2011 and 2014. He is a clinician, academic, and a researcher in the fields of sexual medicine, infertility, and prostatic diseases. His 209 articles were published in peer-reviewed journals, and these articles have received 3734 citations. He is a member of the guideline committee for sexual and reproductive health of the EAU.

He participated the educational programs on sexual medicine in San Francisco Faculty of Medicine, California in 1991, and on male infertility at Baylor College of Medicine Houston/Texas in 1994.

He is a member of the ESSM, EAU, AUA, ISSM, ISWISH, and ASRM. He contributed as a reviewer to the journals *European Urology*, *Journal of Sexual Medicine*, *Andrology*, *Asian Journal of Andrology*, *Andrologia* and *World Journal of Clinical Urology*. He is a board member of the European Section of Andrological Urology (ESAU).

He chaired the 6th South Eastern European Meeting (SEEM) organised by the EAU in October 1–2, 2010, and the European Sexual Medicine Congress (ESSM) in January 29th- February 2nd, 2014, in Istanbul. He served as a committee member at FSD pathophysiology in the 2nd International Erectile and Sexual Function consultation, and as chairman of the Priapism Committee at the 3rd International Erectile and Sexual Function consultation. He participated in the Peyronie Disease Committee in the 4th International Erectile and Sexual Function consultation.

Ateş Kadioğlu is married and has two children. He speaks English and German.

## **Daniel Kelly, PhD**

Dr. Daniel Kelly is a senior lecturer in Biochemistry at Sheffield Hallam University with research interests in cardiovascular disease, type 2 diabetes, obesity and the role of testosterone in these diseases. Following his PhD studying the anti-inflammatory effects of testosterone on atherosclerosis, Daniel undertook a postdoc at the University of Sheffield to work with Professor Hugh Jones to investigate the tissue-specific actions of testosterone related to the pathogenesis of type 2 diabetes and cardiovascular disease. This research continues at Sheffield Hallam University and extends through on-going collaborations with partners at the University of Sheffield, University of Chile, Barnsley NHS

foundation trust and Bayer Healthcare where he is currently using cell culture systems, pre-clinical models and medical trials of replacement therapy to uncover the underlying mechanisms of testosterone action. Daniel has an honorary lectureship position at the University of Sheffield allowing close collaboration across the Sheffield Universities. He is the deputy course leader for the undergraduate Biomedical Science degree at Sheffield Hallam University where he uses his current and prior research to inform his teaching in areas related to metabolism, endocrinology, cell biology, and biological basis of disease.

## **Mohit Khera, MD, MBA, MPH**

Dr. Khera earned his undergraduate degree at Vanderbilt University. He subsequently earned his Masters Degree in Business Administration and his Masters Degree in Public Health from Boston University. He received his Medical Degree from The University of Texas Medical School at San Antonio and completed his Residency training in the Scott Department of Urology at Baylor College of Medicine. After finishing a six-year residency in Urology, he completed a one-year fellowship in Male Reproductive Medicine and Surgery.

Currently he is a Professor in the Scott Department of Urology at Baylor College of Medicine and holds the F. Brantley Scott Endowed Chair in Urology. He specializes in Male Infertility and Male and Female Sexual Dysfunction and testosterone therapy. He also serves as the Director of the Laboratory for Andrology Research at Baylor College of Medicine and Medical Director of the Houston Hospital for Specialized Surgery. He was recently appointed as the Medical Director for Baylor College of Medicine's Executive Health Program.

Dr. Khera is an enthusiastic investigator in the laboratory. In 2006 he was awarded the American Urological Association and Pfizer Scholars Grant to study erectile dysfunction; in 2007 he was awarded an Auxilium Pharmaceutical Grant to study testosterone replacement therapy for prostate cancer patients, and in 2008 he was awarded an Allergan grant to study the effects of botulinum toxin in treating Peyronie's disease. These studies continue, and in 2012 Dr. Khera was awarded one of 2 national grants to study sexual dysfunction in men taking finasteride. Also in 2012 he patented a new delivery system for testosterone and currently his laboratory is studying stem cells to treat sexual dysfunction.

He is a widely published writer, having co-authored book chapters including those for the acclaimed Campbell-Walsh Urology textbook, for Clinical Gynecology, and for the fourth edition of Infertility in the Male edited by Lipshultz, Howards, and Niederberger. He also co-edited the third and most recent edition of the popular book Urology and the Primary Care Practitioner. In 2014 he published his second book "Recoupling: A Couple's 4 Step Guide to Greater Intimacy and Better Sex". Dr. Khera has published over 100 articles in scientific journals and has given over 200 lectures throughout the world on testosterone replacement therapy and sexual dysfunction.



# SPEAKER BIOGRAPHIES

Dr. Khera currently serves as an active member in the Sexual Medicine Society of North America and the American Society of Andrology. In 2014 he became Associate Editor of the Journal of Sexual Medicine. He currently serves on the American Urologic Association (AUA) Examination Committee and Sexual Dysfunction Guidelines Committee. He teaches courses on low testosterone and sexual dysfunction for the AUA locally and internationally.

Dr. Khera freely shares his time and knowledge with the general public. He has been voted one of Houston's Best Doctors by Health and Sport Fitness Magazine and is a frequent guest on such TV programs as Fox News' "Ask the Doctor." He also writes a blog on Men's Health for the Houston Chronicle Newspaper.

## **Jason Kovac, MD, PhD, MSc, FRCSC**

Dr. Jason Kovac is a Fellow of the Royal College of Surgeons of Canada (FRCSC), the American College of Surgeons (FACS) and a Diplomate of the American Board of Urology. He currently serves as the Director of the Men's Health Center in Indianapolis, Indiana. He is also a voluntary Clinical Assistant Professor at Indiana University and Marian University. After obtaining his concurrent Bachelor of Science and Education degrees at York University (Toronto, ON, Canada) he went on to complete a Master of Science degree at Queen's University (Kingston, ON, Canada) with a focus on ion channels and glandular ion secretion. He then completed studies in calcium imaging and patch-clamp electrophysiology of isolated smooth muscle cells during his concurrent MD and PhD degrees at Western University (London, ON, Canada). This was followed by a urology residency at McMaster University (Hamilton, ON, Canada) and a combined clinical and research fellowship in Male Reproductive Medicine and Surgery with Drs. Lipshultz and Lamb at the Baylor College of Medicine (Houston, TX) sponsored by the National Institutes of Health (NIH).

His clinical interests include advanced hypogonadism, male infertility and reproductive endocrinology and microsurgery as well as erectile dysfunction and penile prostheses. Dr. Kovac has been the recipient of numerous training and travel awards to both national and international conferences for his clinical and research endeavors. He has also been awarded an NIH Urologic Research Career Development Award, a Canadian Institutes of Health Research (CIHR) MD/PhD Fellowship, and a Natural Engineering Research Council of Canada (NSERC) Postgraduate Scholarship. To date, Dr. Kovac has published over 100 scientific papers and review articles in peer-reviewed scientific journals and authored multiple book chapters in Men's Health and Reproductive Medicine.

## **Larry I. Lipshultz, MD**

Dr. Lipshultz is Professor of Urology and Chief of the Scott Department of Urology's Division of Male Reproductive Medicine and Surgery at Baylor College of Medicine in Houston, Texas. Dr. Lipshultz, who holds the Lester and Sue Smith Chair in Reproductive Medicine, is a well-known authority on abnormalities of male reproduction, erectile dysfunction, and male hormone therapy. He has published more than 425 journal articles, edited over 10 books, and has instituted a fellowship training program in male reproductive medicine and surgery that has trained more than 120 physicians, who are now in practice both here and abroad.

## **Martin M. Miner, MD**

Dr. Miner is Director of the Men's Health Center of Miriam Hospital, in Providence, Rhode Island. He is a Clinical Professor of Family Medicine and Urology at Warren Alpert Medical School of Brown University, in Providence, and Co-Director of the Men's Health Center there. Dr. Miner graduated Phi Beta Kappa from Oberlin College and received a Doctor of Medicine degree from the University of Cincinnati College of Medicine, both in Ohio. He completed a residency at Brown University and worked with the Indian Health Service Corps and the Public Health Service. Active on several journal editorial boards, Dr. Miner also serves as a reviewer and has published extensively in the areas of erectile dysfunction, cardiovascular disease, benign prostatic hyperplasia, lower urinary tract symptoms, male sexuality, and hormone therapy for men. He has given numerous presentations in the United States and internationally, is active in several research studies on men's health, and is a consultant to the International Society of Sexual Medicine Consensus Panel.

Dr. Miner holds memberships in the American Academy of Family Physicians and the American Urologic Association and was elected a Fellow of the Sexual Medical Society of North America where he was on the BOD until this year. He was chosen the Brown Teacher of the Year in 2003 and 2007 and was recognized with the Massachusetts Medical Societys Award on greatest contribution to Mens Health: 2012.

## **Abraham Morgentaler, MD, FACS**

Dr. Morgentaler, the Director of Men's Health Boston, is an Associate Clinical Professor of Urology at Beth Israel Deaconess Medical Center and Harvard Medical School. Dr. Morgentaler lectures nationally and internationally to teach physicians the latest information in the diagnosis and treatment of conditions affecting men's sexual and reproductive health. His primary areas of interest are testosterone deficiency, male sexual dysfunction, and prostate cancer. He is the President of the Androgen Society, an international multidisciplinary professional organization that promotes research and education regarding testosterone deficiency and its treatment.

Dr. Morgentaler has published over 200 scientific articles and textbook chapters. He is a regular contributor to television and radio shows addressing male issues, and has appeared on NBC Nightly News, CBS Evening News, CNN with Anderson Cooper, and The Connection on NPR. Dr. Morgentaler and his clinical work with testosterone were featured in The New Yorker, and his comments have been published in journals such as Newsweek and US News and World Report.

He is the author of several popular books, including, The Truth About Men And Sex: Intimate Secrets From the Doctor's Office, The Viagra Myth: The Surprising Impact on Love and Relationships, and Testosterone for Life: Recharge Your Vitality, Sex Drive, Muscle Mass, and Overall Health



# SPEAKER BIOGRAPHIES

## **Sharon J. Parish, MD, IF**

Dr. Sharon J. Parish is a Professor of Medicine in Clinical Psychiatry and Professor of Clinical Medicine at the Weill Cornell Medical College and the Director of Medical Services at the New York Presbyterian Hospital/Westchester Division. Dr. Parish is an internal medicine physician who is a fellow of the International Society for the Study of Women's Sexual Health (ISSWSH) and a North American Menopause Society Certified Menopause Practitioner. She has an internal medicine practice focusing on sexual medicine for female and male patients at Weill Cornell Medicine in New York City.

Dr. Parish has a special interest in practice, training, and research in sexual medicine and menopause. She has designed many educational programs on sexual health and sex medicine communication skills for undergraduate, graduate, and postgraduate medical education and across multiple disciplines. She has authored many publications and online materials on an array of topics including female and male sexual dysfunction classification, clinical assessment, and therapeutic interventions; sexuality communication skills and education; erectile dysfunction, premature ejaculation, hormonal therapy, and genitourinary syndrome of menopause/vulvovaginal atrophy. Her academic activities have also included participation in international and national society committees and consultancies; lectures, symposia, and web-based educational programs; and sexual medicine society leadership roles.

She is Past President of the ISSWSH (2014-2018), Chair of the ISSWSH Clinical Practice Guidelines Committee (2016-2022), a member of the ISSWSH Board of Directors (2001-present), the ISSWSH Scientific Program Chair (Annual Meetings 2018, 2019), and was Chair of the ISSWSH Education Committee from 2002-2014. She is a member of the International Society for Sexual Medicine (ISSM) Board of Directors (2018-2022) and Education and Corporate Relations Committees. Dr. Parish is an Associate Editor for Sexual Medicine Reviews (2017-present) and previously Associate Editor for CME (2006-2014) and Assistant Editor for Female Medical/Surgical for the Journal of Sexual Medicine (2014-2016).

## **Omer Raheem, MD**

Dr. Raheem is a fellowship-trained urologist and Director of the Men's Health at Tulane Urology-Garden District and Tulane University Assistant Professor of Urology and its affiliated teaching hospitals and clinics. He completed his urology residency at the University of California, San Diego and then completed fellowship at the University of Washington, Department of Urology, specializing in Male Reproductive, Sexual Medicine and Surgery under Dr Thomas Walsh and Hunter Wessells. Prior to his US training, Dr Raheem awarded the membership of the Royal College of Surgeons in United Kingdom and Ireland following the completion of Basic Surgical Training (CCBST).

During his training, he accrued multiple certifications and contributed to a wide array of medical texts including numerous research abstracts, multiple publications by highly reputable journals and several book chapters totaling over 100 peer-reviewed published articles and book chapters. He awarded several prestigious research prizes including the Best Poster at

the annual meeting of the American Urological Association in Washington, DC in 2011 and New Orleans, LA 2015, San Diego Urological Society, Resident Essay Contest Western section AUA in 2016 and 2017, San Diego Urological Society, honorable mention, Annual Research Resident Contest in 2016 and George W. Kaplan Outstanding Research Resident for three consecutive years 2015-2017. In addition, he awarded the Coloplast research grant and travel award, Minnesota in 2016 and holds a patent for a xenograft model of human bone metastatic prostate Cancer developed at the University of California, San Diego, Moores Cancer Center prostate cancer research laboratory in 2013.

Dr. Raheem's clinical and research interests include all aspects of male reproductive and sexual dysfunction. He believes in a comprehensive and multidisciplinary approach to the evaluation and treatment of male infertility, erectile and sexual dysfunction and mens health conditions. He works closely with experts in Reproductive Endocrinology and Infertility to offer comprehensive care to infertile couples. He integrates the most advanced and minimally invasive diagnostic and treatment modalities into his practice including microsurgical sperm retrieval, vasectomy reversal, varicocele surgery and complex penile reconstruction. Since moving to New Orleans, Louisiana, Dr Raheem's goal is to establish state-of-the art Men's Health Center at Tulane Urology's Garden District to serve as a gateway to bring men into the medical setting to help them arrive to best solution for complex men's health issues.

## **Sudarshan Ramachandran, PhD, FRCPath**

Originally from Sri Lanka, Professor Ramachandran trained as an undergraduate in London (Imperial College, University of London) and was accepted onto the specialist training programme in Chemical Pathology in the West Midlands. He was appointed a Consultant Chemical Pathologist at the University Hospitals Birmingham and Senior Lecturer at the University of Birmingham in 2000. He completed a PhD in 2004 conducting research into the role of genetics in cancer, using basal cell carcinoma as a cancer model. The work then went on to include other conditions associated with UV exposure such as prostate cancer and multiple sclerosis.

In 2015 he was appointed to the newly created chair of Metabolic Medicine at the University Hospitals of North Midlands. His work on blood flow characteristics enabled him to be appointed as Professor (Hon) of Biomedical Engineering at Brunel University London. Professor Ramachandran's research and clinical work is now focussed on the Metabolic Syndrome, its components and associated conditions including obesity, diabetes/pre-diabetes, dyslipidaemia, hypertension, non-alcoholic fatty liver disease, testosterone deficiency and cardiovascular disease prevention.

# SPEAKER BIOGRAPHIES

## **Ranjith Ramasamy, MD**

Ranjith Ramasamy is the Director of Reproductive Urology as well as an Associate professor in Department of Urology at the University of Miami. As a Urologist and Microsurgeon, Dr. Ramasamy specializes in the treatment of disorders of male infertility and sexual dysfunction and an expert in vasectomy reversal and penile prosthesis. Dr. Ramasamy completed his Urology residency training at Weil Cornell Medical College and New York-Presbyterian Hospital. He then completed a National Institutes of Health sponsored fellowship in Male Reproductive medicine and Surgery at Baylor College of Medicine. In addition to his clinical accolades, Dr. Ramasamy has been integral to the advancement of male reproductive medicine and surgery. To date, he has published over 300 manuscripts in peer-reviewed journals and several book chapters; he currently serves on editorial board for *Urology*, and *Asian Journal of Andrology* and as an editorial reviewer for *Journal of Urology*, *European Urology* and *British Journal of Urology*. Furthermore, he has been invited to lecture at numerous international conferences including the American Urological Association, Malaysian and Indian Society of Assisted Reproduction.

## **Sophie Reisz**

Sophie Reisz is the Vice President and Executive Editor at Mary Ann Liebert, Inc., publishers. Along with personally overseeing the growth and development of *Androgens*, the official journal of the Androgens Society, together with Drs. Abdul Traish and Abraham Morgentaler, she oversees the editorial quality, impact, and success of the entire Liebert journal portfolio and special content projects.

## **Farid Saad, DVM, PhD**

Farid Saad worked for various pharmaceutical companies as specialist for reproductive endocrinology, pediatric endocrinology, andrology, endocrinology of male aging, and hormonal male contraception in clinical development andrology, scientific and global medical affairs. He retired in 2019 and keeps working as consultant for Bayer AG in Germany. Farid Saad has authored and co-authored more than 150 peer-reviewed papers and more than 700 scientific abstracts. He received honorary professorships in clinical research and endocrinology at Gulf Medical University, Ajman, United Arab Emirates, and at Men's Health Reproduction Study Center, Hang Tuah University, Surabaya, Indonesia, and serves as a lecturer at Dresden International University.

## **Allen D. Seftel, MD, FACS**

Dr. Seftel is Chief of Urology at Cooper University Hospital, and Professor of Urology at Cooper Medical School at Rowan University, Camden, NJ, since October 2009. In 2013, Dr. Seftel received an adjunct appointment at the MD Anderson Cancer Center. Effective January 2015, Dr. Seftel became the director of the fully accredited Cooper University Hospital urology residency program. Dr. Seftel received his undergraduate degree (BA) at New York University in Chemistry and his M.D. at the State University of New York Downstate Medical Center in Brooklyn in 1984 in medicine. He completed his urology residency at Case Western Reserve University and then spent over two years at an American Foundation for Urologic Disease Scholar in sexual dysfunction at the Boston University School of Medicine under the auspices of the late Doctor Robert Krane and Doctor Irwin Goldstein.

In 1992, Dr. Seftel returned to Case Western Reserve University and directed a very successful and world-renowned sexual dysfunction clinic at University Hospitals of Cleveland as well as the Cleveland VA Medical Center until his relocation to Camden, NJ in 2009. He received his award of Professor of Urology in July 2004. Dr. Seftel's research interests include BPH, male hypogonadism, male erectile dysfunction, as well as ejaculatory dysfunction. Since 2002, Dr. Seftel has served as the editor of the topic area "Sexual Dysfunction" for the Journal of Urology's Urologic Survey Section. Of note, Dr. Seftel was appointed as the editor-in-chief of the Internal Journal of Impotence Research from 2004-2009, and currently serves on numerous editorial boards.

Importantly, Dr. Seftel has lectured nationally and internationally on all aspects of male sexual health, including hypogonadism, and has written extensively on the topic of male hypogonadism, including 2 recent publications on hypogonadism in the Mayo Clinic Proceedings. The American Urological Association awarded Dr. Seftel with a Presidential Citation for his service to the Urology Care Foundation at its 2015 annual meeting. Dr. Seftel is the current president of the American Society of Men's Health.

## **Ronald Swerdloff, MD**

Dr. Swerdloff is a Distinguished Professor, and Chief of the Division of Endocrinology at Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA; Senior Scientist at the Lundquist Research Institute; Director of a NIH sponsored Contraceptive Clinical Trials Network Center and project Investigator on a NICHD P-50 Center Grant. A former Editor of the Journal of Clinical Endocrinology and Metabolism, he has published over 500 peer-reviewed articles, and many reviews, chapters and books. His research includes basic investigations, clinical trials and translational studies bridging the two branches of biomedical science. He is the recipient of the Distinguished Educator Award from the Endocrine Society, Distinguished Andrologist Award from the American Society of Andrology and the prestigious Mellinkoff Award from UCLA School of Medicine for superior translation of science from bench to bedside. He has a long history of funding from the NIH.

## **Abdulmaged M. Traish, MBA, PhD**

Dr. Traish earned a B.Sc., in Chemistry and Botany from the University of Tripoli, Tripoli, LIBYA in 1971 and a PhD, in Biochemistry from Boston University, Boston, MA in January of 1978. After two years of training as a postdoctoral Fellowship in the Department of Biochemistry at Boston University school of Medicine, he was appointed as an assistant research professor of Biochemistry. Professor Traish also earned Master of Business Administration (MBA) from Boston University School of Management in 1993. Since 1979, Dr. Traish was collaborating with faculty in the Urology Department and in 1996 he was promoted to full professor in the Department of Biochemistry and Department of Urology.

# SPEAKER BIOGRAPHIES

Professor Traish pursued basic research, in the field of steroid biochemistry and physiology of reproductive and sexual medicine. His contributions to the field of sexual medicine include the development of experimental animal models to investigate the endocrine regulation of sexual arousal physiology and function in males and females and his pioneering work on the basic mechanisms of sex steroid hormones on erectile physiology. Professor Traish has been successful in procuring research funds from the National Institute of Health as well as from the Private Sector and was instrumental in the establishment of the institute for sexual medicine at Boston University school of Medicine. Dr. Traish is a researcher with renowned national and international reputation.

## **Christina Wang, MD**

Dr. Christina Wang is a Professor of Medicine and Assistant Dean at the David Geffen School of Medicine at UCLA and Associate Director for Clinical and Translational Science Institute and a faculty member of the Division of Endocrinology, Department of Medicine, Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute, Torrance, California.

Dr. Wang has been involved in many funded basic and clinical research studies. Her current clinical research studies include androgen replacement therapy, hormonal male contraceptive development, late onset hypogonadism, accurate assessment of serum androgens, and diet and androgen metabolism. Her basic research studies are focused on the regulation of spermatogenesis. She has authored over 280 peer-reviewed publications, 67 chapters and reviews mainly on male reproductive biology including characterization of the pharmacokinetics and efficacy of androgens in men, trials of hormonal male contraceptive, regulation of germ cell apoptosis, and reproductive aging. Dr. Wang served on the Executive Council, several committees and was the President of the American Society of Andrology (2006-2007). She also served the International Society of Andrology as Secretary (2001 to 2005), chair of the Program Organizing Committee (2005 to 2009). She was President of the International Society of Andrology 2009-2013. She is a member of the Research Group on Methods for the Regulation of Male Fertility of the World Health Organization since 1984 and Chairperson 1991-2002.

She has mentored many physician and scientist and is an advocate of young investigators. Dr. Wang has been invited speaker and distinguished lecturer at many national and international endocrinology, reproductive endocrinology and andrology conferences.

## **Bu Beng Yeap, MBBS, FRACP, PhD**

Dr. Bu Yeap is a Professor in the Medical School, University of Western Australia, and a consultant endocrinologist in the Department of Endocrinology and Diabetes at Fiona Stanley Hospital, Perth, Western Australia. He provides inpatient and outpatient care at Fiona Stanley Hospital, mentors early and mid-career researchers, supervises PhD students and physician trainees, and teaches medical students. His research program focusses on epidemiological and clinical studies of hormones and health outcomes in men. These include testosterone and male ageing, the relationship between testosterone and cardiovascular risk in men, and the interaction between hormones, diabetes

and cardiovascular risk. Bu was first author on the Endocrine Society of Australia's Position Statement on Management of Male Hypogonadism published in the Medical Journal of Australia in 2016. He was an investigator in the Testosterone for the Prevention of Type 2 Diabetes Mellitus (T4DM) study, an Australia-wide randomised controlled trial of testosterone to prevent or revert type 2 diabetes in men at high risk. He is currently President of the Endocrine Society of Australia (2020-22). To date he has ~250 publications (including ~200 original research articles) with >7000 cites.

## **Michael Zitzmann, MD, PhD**

Professor Michael Zitzmann, born in 1964, is a high school teacher specialised in the fields of endocrinology, diabetology, sexual medicine and andrology at the University Clinics of Muenster, Germany.

He is specialised in patient care regarding diabetes mellitus, thyroid disorders and problems of the pituitary gland. In addition, he is also focussing on endocrinological andrology: boys with pubertal disorders up to older men with a variety of sexual and metabolic problems seek his advice.

Also couples with fertility problems form a major part of the patient clientele, as well as men with chronic inherited hormone disorders requiring life-time attention, especially Klinefelter Syndrome.

Prof. Zitzmann has developed treatment programs for the induction of fertility in hypogonadal men. He is largely involved in the research of the interplay of genetic issues, hormones, psychological characteristics and obesity treatment.

Prof. Zitzmann has received several international awards and grants in recognition of his work and is a member of international committees, journal editorial boards and is on the Board of the German Society for Andrology and the German Adiposity Foundation. He is invited world-wide for consultations and lectures.

# SATELLITE SYMPOSIUM

## INDUSTRY SATELLITE SYMPOSIUM EVENT

SATURDAY, APRIL 23, 2022

12:15 p.m. - 1:15 p.m.

**Industry Satellite Symposium Lunch**

*Location: Palm DE*

**Making a Case for Individualized Treatment for Testosterone Deficiency**

Speaker: Parviz K. Kavoussi, MD, FACS

***Sponsored By: Acerus Pharmaceuticals Corporation***



# INDUSTRY SUPPORT

THANK YOU TO OUR 2022  
PROMOTIONAL PARTNERS

Platinum Level Partner



Gold Level Partner



# INDUSTRY SUPPORT

## THANK YOU TO OUR 2022 EXHIBITORS

---


Acerus Pharmaceuticals

Antares Pharma

Endo Pharmaceuticals

Fellow

# EXHIBIT HALL FLOOR PLAN



Company Name	Table #
Acerus Pharmaceuticals Corporation	1
Antares Pharma	2
Endo Pharmaceuticals	4
Fellow	3



# Androgen Society

**The Androgen Society**

Two Woodfield Lake  
1100 E. Woodfield Road, Suite 350  
Schaumburg, IL 60173

**(847) 517-7225**

**Contact@androgensociety.org**